Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases)?
By:
References
- 1. Elias D, Mariani A, Cloutier A, Blot F, Goéré D, Dumont F et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. European Journal of Surgical Oncology (EJSO). 2014;40(11):1467-1473
- 2. Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 2010;376(9742):687-697.
- 3. Al-Batran S, Homann N, Pauligk C, Illerhaus G, Martens U, Stoehlmacher J et al. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer. JAMA Oncology. 2017;3(9):1237.
- 4. Sugarbaker P. Peritonectomy Procedures. Annals of Surgery. 1995;221(1):29-42.
- 5. Piso P, Leebmann H, März L, Mayr M. Zytoreduktive Chirurgie für maligne Tumoren des Peritoneums. Der Chirurg. 2014;86(1):38-46.
- 6. Jacquet, P., Sugarbaker, P. H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer treatment and research. 1996;
82 , 359-374. - 7. Chua T, Yan T, Saxena A, Morris D. Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?. Annals of Surgery. 2009;249(6):900-907.
- 8. Chia C, You B, Decullier E, Vaudoyer D, Lorimier G, Abboud K et al. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?. Annals of Surgical Oncology. 2016;23(6):1971-1979.
- 9. Yang X, Huang C, Suo T, Mei L, Yang G, Cheng F et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial. Annals of Surgical Oncology. 2011;18(6):1575-1581.
10.1245/s10434-011-1631-5 - 10. Rudloff U, Langan R, Mullinax J, Beane J, Steinberg S, Beresnev T et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial. Journal of Surgical Oncology. 2014;110(3):275-284.
- 11. Canbay E, Mizumoto A, Ichinose M, Ishibashi H, Sako S, Hirano M et al. Outcome Data of Patients with Peritoneal Carcinomatosis from Gastric Origin Treated by a Strategy of Bidirectional Chemotherapy Prior to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in a Single Specialized Center in Japan. Annals of Surgical Oncology. 2013;21(4):1147-1152.
- 12. Boerner T, Graichen A, Jeiter T, Zemann F, Renner P, März L et al. CRS-HIPEC Prolongs Survival but is Not Curative for Patients with Peritoneal Carcinomatosis of Gastric Cancer. Annals of Surgical Oncology. 2016;23(12):3972-3977.
- 13. Desiderio J, Chao J, Melstrom L, Warner S, Tozzi F, Fong Y et al. The 30-year experience—A meta-analysis of randomised and highquality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. European Journal of Cancer. 2017;79:1-14.
10.1016/j.ejca.2017.03.030
Language: English
Page range: 207 - 210
Submitted on: Dec 18, 2017
Accepted on: Dec 29, 2017
Published on: Mar 9, 2018
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2018 Sebastian Blaj, Pompiliu Piso, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.